Clinical Trial Update: Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating olanzapine to manage cancer-associated anorexia in head and neck cancer patients undergoing chemoradiation (MACRO Trial).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer-associated Anorexia
• Head and Neck Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma of Unknown Primary

Drugs mentioned

• olanzapine (olanzapine)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING